This rewired metabolism is a putative therapeutic target for the treatment of KRAS mutant CRC or to overcome therapeutic resistances, with pormising responses in vitro [48] and phase 1 or 2 ongoing [28]. This evidence concerns the gene KRAS and colorectal carcinoma.